Small Cap Feast
Small Cap Feast – 26 February 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
FRP Advisory Group, UK professional services firm specialising in restructuring advisory. Raising £80m (£20m primary). Expected market cap £190m. Compound annual growth of 16.4 per cent. in revenue and 10.9 per cent. in operating profit since the beginning of FY17.o Strong average EBITDA margins of 51 per cent. over FY17 to FY19, and consistently strong cash conversion
Inspecs, a UK designer, manufacturer and distributor of eyewear frames to global retail chains announces its intention to IPO onto AIM raising £94m with a market cap of £138m. Admission expected 27th February. FY Dec 2018 numbers show revenue of $57m and underlying EBITDA of $11m
Main Market (Standard List)
The Proof Of Trust has announced its intention to list on the Standard Market. The Blockchain based business, owns patents to a protocol which facilitates dispute resolution based upon smart contract disputes. Transaction details TBC.
Main Market (Premium)
DRI Healthcare—investment company focused on investments in healthcare Royalty Assets looking to raise $350m. Due 11 Mar.
Ninety One –proposed demerger and public listing of Investec’s global asset management business on LSE and JSE. 30 Sep 2019 AUM £121bn. Sale of existing shares. Expected free float of >60%. Due 16 march.
Cabot Square—Closed ended investment fund focussed on alternative assets and asset manager. Looking to raise £200m. Will target investment opportunities that are expected to generate an attractive risk adjusted return and that can also make a positive ESG impact by focusing on some of the biggest challenges facing societies and economies. Due 14 Feb.
The Global Sustainable Farmland Income Trust will invest in a diversified portfolio of operational farmland assets located in major agricultural markets including the United States, Europe, New Zealand, Australia and certain countries within Latin and South America. Raising up to $300m. Due 28 February.
Incanthera—Specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive . Due 28 Feb.
Zapp Scooters, a developer and manufacturer of electric two-wheeled vehicles announced its intention to IPO on the NEX Exchange Growth Market. The Company intends to raise up to £3.5m. Admission is expected to occur on NEX in February 2020.
REACT Group (REAT.L) 0.75p £3.12m
AGM Statement. The REACT specialist cleaning business continues to trade well. In the period since the 30 September 2019 year end, margins and operational efficiency have continued to improve with maintained focus on quality of earnings and increasing business activity in sectors in which REACT provides the greatest value.
Progress is underpinned by recent contract wins, including the incremental half am-pound specialist cleaning contract in the rail sector, announced 23 January 2020, and the £121,000 deep cleaning contract at a large London hospital, announced 3 February. Furthermore a 3-year framework agreement has recently been awarded by another existing client, a large housing association in the North West of England.
Symphony Environmental Technologies* (SYM.L) 13.5p £22.9m
Symphony announced breakthrough in the United States, following approval from the U.S. Food & Drugs Administration (FDA) for its d2p antimicrobial technology, for use in polyethylene (LLDPE) film for wrapping bread. Approval, which is not time limited, has been given under the Food Contact Notification procedure.
By virtue of the Federal Food Drug and Cosmetic Act (21 USC 348(h)(2)(C)) this approval is effective only for Symphony and does not include any similar or identical substance manufactured or prepared by a company or person other than Symphony. This approval therefore provides Symphony with a new and immediate commercial opportunity in the western world’s largest market, as well as in other markets which expect to see FDA approval.
This technology is intended to inhibit the growth of bacteria on the surface of the packaging film.
Kropz (KRPZ.L) 10.5p £29.76m
The emerging African phosphate explorer and developer, announces that Mr Ian Harebottle has resigned as its Chief Executive Officer and director, with effect from 29 February 2020. As a result of Mr Ian Harebottle’s resignation, the Board has appointed Mr Mark Summers, currently the Company’s Chief Financial Officer, as its interim CEO.
Kropz also announces that its 74% subsidiary, Kropz Elandsfontein (Pty) Ltd has entered into a R30m (approximately US$1.98m) loan facility with Kropz’s major shareholder, the ARC Fund ARC is also Kropz Elandsfontein’s 26% black economic empowerment shareholder in South Africa. This facility is necessary to enable Kropz Elandsfontein to progress with the execution of the modifications required at the Elandsfontein phosphate project, as detailed in the Company’s announcement on 14 February 2020, which noted that additional processing equipment and infrastructure are required to deliver a consistent and saleable concentrate product.
Plexus Holdings (POS.L) 26.5p £26.6m
The oil and gas engineering services business and owner of the proprietary POS-GRIP® friction-grip method of wellhead engineering, announced that its Russian licensee, LLC Gusar has placed an order for an additional set of POS-GRIP® exploration rental jack-up drilling wellhead equipment. This purchase by Gusar is in response to encouraging discussions between Gusar and its customers following the successful installation of a first POS-GRIP rental gas exploration wellhead in Russia for Gazprom (see announcement of 24 September 2019 for further details). Pricing for the equipment was at market rates and payment will be in cash.
“The acquisition of additional POS-GRIP® exploration wellhead equipment by our licensee Gusar, so soon after the successful installation of the first POS-GRIP wellhead for major Gazprom, is highly encouraging and bodes well for Gusar securing further orders in Russia. ”
Fiske (FKE.L) 59p £6.9m
HY Nov 19 results. Pre-tax operating loss of £158,000 compared to a loss of £344,000 for the comparable period in 2018.
Fee and commission revenues were some £334,000 higher than the prior year comparative which represents an improvement of approximately 15%. Within this investment management fee revenues grew by 19% whilst commission revenues increased by 12% when compared to the equivalent period to 30 November 2018. This has delivered total revenues of £2.509m (2018: £2.163m) which is a result of generally improved market conditions and the continued migration of clients to fee paying services.
Assuming no significant deterioration in trading conditions, the board remains confident that the Group will continue to make further progress in 2020.
Zegona Comms (ZEG.L) 104.5p £230.8m
Euskaltel (Zegona 20%) returns to growth. Euskaltel yesterday reported its Q4 2019 and FY 2019 results, with significantly improved operating KPIs for the year. In 2019, Euskaltel grew its fixed subscribers by 9k, with 18k broadband net additions and 47k postpaid mobile net additions. This is the first year of customer growth after two years of losses. The number of products and services also grew with more convergent customers, reaching an average of almost 3.7 services per subscriber. In the B2B market, Euskaltel similarly increased its customer base materially during 2019, reaching a record high of 15.3k customers. EBITDA for Q4 2019 reaching a record level of €92m, an increase of almost 8%
Reabold Resources (RBD.L) 0.59p £39m
Update regarding its operations in California.
- VG-6 well on West Brentwood tested at 350 mscf/d and now on permanent production
- New play at West Brentwood field opened up, providing additional follow on targets
- Gross oil production across Reabold California of 50,286 barrels of oil equivalent between July and December 2019 (Reabold 50% equity interest)
- Net revenue to Reabold from hydrocarbon sales in California of USD 1,349,000 between July and December 2019
- Estimated cash operating cost per barrel of oil equivalent of $13
Egdon Resources (EDR.L) 3.9p £11.8m
Update on production for the first half of the Company’s 2019-2020 financial year which ended on 31 January 2020.
Production during the Period was 32,758 barrels of oil equivalent (“boe”), at an average of 178 boe per day (“boepd”) (H1 2019: 30,026 boe, 164 boepd). This is in line with previous guidance for H1 of 170-180 b/d. The previously stated guidance of 130-140 boepd for the full year remains valid. Production was attained from the Ceres gas field and the Keddington and Fiskerton Airfield oil fields.
The Company’s interim results for H1 2020 are scheduled to be announced on 21 April 2020.
Jangada Mines (JAN.L) 2.35p £5.7m
Initial results of the 2020 drilling programme on the Pitombeiras North target at its 100% owned Pitombeiras Vanadium Project (‘Pitombeiras Project’ or ‘the Project’), located in Ceara State, Brazil.
All 3 holes intersected VTM mineralisation
- Results include:
o 38.00 metres at 0.558% vanadium oxide (‘V2O5’), 11.31% titanium (‘Ti’) and 38.40% iron (‘Fe’)
o 32.18 metres at 0.547%, 10.79% Ti and 37.22% Fe, including 13.25 metres at 0.740% V2O5, 14.63% Ti and 48.9% Fe
Microsaic Systems (MSYS.L) 1p £4.6m
The developer of point of need mass spectrometry (“MS”) instruments, is announced that it has signed a global integration and joint sales and marketing heads of terms with Axcend Corp (“Axcend”) to integrate the compact Microsaic 4500 MiD® MS with the portable Axcend Focus LC® (“LC/MS system”), and to commercialise the combined system globally using both companies’ direct sales and selected distribution channels. The Axcend Focus LC® is a very small footprint, high-performance liquid chromatography system (“HPLC”). “We are particularly excited by this partnership, which combines two highly differentiated compact products into a very powerful LC/MS system.”
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.